Recommendations of RAAS Blocker Use Amidst The Coronavirus Pandemic
With a rapidly growing pandemic of coronavirus disease of 2019 (COVID-19), a public health emergency of international concern, the medical communities and national health systems are being tested for their preparedness. The culprit that is responsible for this viral respiratory disease, is a novel...
Main Authors: | Joshua Henrina, doctor, Iwan Cahyo Santosa Putra, doctor, Hoo Felicia Hadi Gunawan, doctor, Irvan Cahyadi, doctor, Leonardo Paskah Suciadi, doctor |
---|---|
Format: | Article |
Language: | English |
Published: |
Indonesian Heart Association
2020-05-01
|
Series: | Majalah Kardiologi Indonesia |
Subjects: | |
Online Access: | http://ijconline.id/index.php/ijc/article/view/1007 |
Similar Items
-
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking
by: Chidinma L. Onweni, et al.
Published: (2020-07-01) -
Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders
by: Aline Silva de Miranda, et al.
Published: (2020-08-01) -
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
by: Gian Paolo Rossi, et al.
Published: (2020-04-01) -
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19
by: Emilia Roy-Vallejo, et al.
Published: (2021-06-01) -
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials
by: Chenhui Tai, et al.
Published: (2017-10-01)